Cargando…

Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function

Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by prolonged inflammation of the gastrointestinal tract. IBD can result from gut barrier dysfunction, altered gut microbiota, and abnormal intestinal immunity induced by environmental factors in genetically suscepti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Son, Mijeong, Park, I Seul, Kim, Soochan, Ma, Hyun Woo, Kim, Ji Hyung, Kim, Tae Il, Kim, Won Ho, Han, Jaeyong, Kim, Seung Won, Cheon, Jae Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174989/ https://www.ncbi.nlm.nih.gov/pubmed/35693794 http://dx.doi.org/10.3389/fimmu.2022.870817

Ejemplares similares

Randomised clinical trial: tegoprazan, a novel potassium‐competitive acid blocker, or lansoprazole in the treatment of gastric ulcer
por: Cho, Yu Kyung, et al.
Publicado: (2020)

Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
por: Lee, Kwang Jae, et al.
Publicado: (2019)

Melatonin controls microbiota in colitis by goblet cell differentiation and antimicrobial peptide production through Toll-like receptor 4 signalling
por: Kim, Seung Won, et al.
Publicado: (2020)

Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
por: Park, Jihye, et al.
Publicado: (2021)

Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: A nationwide cohort study
por: Kim, Min-Gul, et al.
Publicado: (2023)

Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial
por: Choi, Yoon Jin, et al.
Publicado: (2022)

Role of potassium-competitive acid blockers in eradication of Helicobacter pylori infection
por: Kim, Tae Ho
Publicado: (2023)

Novel Histone Deacetylase 6 Inhibitor Confers Anti-inflammatory Effects and Enhances Gut Barrier Function
por: Lee, Jae-Young, et al.
Publicado: (2023)

Succinate-treated macrophages attenuate dextran sodium sulfate colitis in mice
por: Park, I Seul, et al.
Publicado: (2021)

Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study
por: Jeon, Hye Kyung, et al.
Publicado: (2023)

JP‐1366: A novel and potent potassium‐competitive acid blocker that is effective in the treatment of acid‐related diseases
por: Ku, Jin Mo, et al.
Publicado: (2023)

Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori
por: Lee, Jung Won, et al.
Publicado: (2021)

Randomised clinical trial: comparison of tegoprazan and placebo in non‐erosive reflux disease
por: Kim, Seung Han, et al.
Publicado: (2021)

Pathophysiology of Potassium-competitive Acid Blocker–refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test
por: Masaoka, Tatsuhiro, et al.
Publicado: (2018)

Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2022)

Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis
por: Cho, Yu Kyung, et al.
Publicado: (2022)

Efficacy of Seven-Day Potassium-Competitive Acid Blocker-Based First-Line Helicobacter Pylori Eradication Therapy Administered with Bismuth
por: Kim, Ji Yeon, et al.
Publicado: (2021)

Anti-inflammatory properties of butyrate-producing atypical Escherichia coli in a murine colitis model
por: Kim, Ji Hyung, et al.
Publicado: (2023)

Comparison of pharmacokinetic characteristics of two Tegoprazan (CJ-12420) formulations in healthy male subjects
por: Hwang, Jun Gi, et al.
Publicado: (2019)

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
por: Hwang, Sejung, et al.
Publicado: (2021)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
por: Yoon, Deok Y., et al.
Publicado: (2021)

Evaluation of pharmacokinetic drug-drug interaction between tegoprazan and clarithromycin in healthy subjects
por: Oh, Minkyung, et al.
Publicado: (2023)

Potassium-competitive acid blockers and gastroesophageal reflux disease
por: Leowattana, Wattana, et al.
Publicado: (2022)

Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model
por: Kim, Jung Min, et al.
Publicado: (2020)

Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial
por: Kim, Joon Sung, et al.
Publicado: (2023)

Prediction of Drug–Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and Simulation
por: Yoon, Deok Yong, et al.
Publicado: (2021)

Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects
por: Lee, Woo Yul, et al.
Publicado: (2020)

Protonated Form: The Potent Form of Potassium-Competitive Acid Blockers
por: Luo, Hua-Jun, et al.
Publicado: (2014)

The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan
por: Mulford, Darcy J., et al.
Publicado: (2021)

Obesogenic diet-induced gut barrier dysfunction and pathobiont expansion aggravate experimental colitis
por: Lee, June-Chul, et al.
Publicado: (2017)

Anti-Inflammatory Effects of Tegoprazan in Lipopolysaccharide-Stimulated Bone-Marrow-Derived Macrophages
por: Han, Gong-Ho, et al.
Publicado: (2023)

Role of Tegoprazan in Helicobacter pylori Eradication Therapy
por: Lee, Jin
Publicado: (2022)

Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study
por: Han, Sungpil, et al.
Publicado: (2023)

Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?
por: Rawla, Prashanth, et al.
Publicado: (2018)

Gastric polyps' regression after potassium‐competitive acid blocker cessation
por: Iwamuro, Masaya, et al.
Publicado: (2022)

Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
por: Park, Chan Hyuk, et al.
Publicado: (2022)

Triggering Receptor Expressed on Myeloid Cells-1 Agonist Regulates Intestinal Inflammation via Cd177(+) Neutrophils
por: Seo, Dong Hyuk, et al.
Publicado: (2021)

Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study
por: Jung, Yoon Suk, et al.
Publicado: (2023)

Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
por: Lee, Yong Il, et al.
Publicado: (2021)

Hypercontractile esophagus responsive to potassium-competitive acid blockers: a case report
por: Shao, Yuyang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mumtggis3uf09qm6l4if5uce1t